Carisma Therapeutics Inc. (CARM)
undefined
undefined%
At close: undefined

Company Description

Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors.

Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases.

Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc.

Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017.

The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.

Carisma Therapeutics Inc.
Carisma Therapeutics Inc. logo
Country United States
IPO Date Feb 6, 2014
Industry Biotechnology
Sector Healthcare
Employees 107
CEO Steven Kelly

Contact Details

Address:
3675 Market St.
Philadelphia, Pennsylvania
United States
Website https://carismatx.com

Stock Details

Ticker Symbol CARM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001485003
CUSIP Number 14216R101
ISIN Number US14216R1014
Employer ID 26-2025616
SIC Code 2834

Key Executives

Name Position
Steven Kelly President, Chief Executive Officer & Director
Richard S. Morris CPA Chief Financial Officer, Chief Compliance Officer, Treasurer, Prin. Financial Off. & Prin. Acc. Off.
Dr. Eugene P. Kennedy F.A.C.S., M.D. Chief Medical Officer
Dr. Saar Gill M.D., Ph.D. Co-Founder & Chairman of Scientific Advisory Board
Eric H. Siegel J.D., MBA General Counsel & Corporate Secretary
Kenneth Locke Senior Vice President of Technical Operations
Michael Klichinsky Ph.D., Pharm.D., PharmD Co-Founder & Chief Scientific Officer
Terry Shields Senior Vice President of Human Resources
Tom Wilton Chief Business Officer

Latest SEC Filings

Date Type Title
Dec 09, 2024 8-K Current Report
Nov 07, 2024 10-Q Quarterly Report
Nov 07, 2024 8-K Current Report
Nov 01, 2024 4 Filing
Nov 01, 2024 3 Filing
Oct 30, 2024 8-K Current Report
Oct 11, 2024 8-K Current Report
Aug 08, 2024 10-Q Quarterly Report
Aug 08, 2024 8-K Current Report
Jul 09, 2024 8-K Current Report